Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
Heinz‐Josef LenzMedical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USAEric Van CutsemDigestive Oncology, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, BelgiumMaría Luisa LimónMedical Oncology, Hospital Universitario Virgen del Rocio, Seville, SpainKa Yeung Mark WongMedical Oncology, Westmead Hospital, Sydney, AustraliaAlain HendliszInternal Medicine, Institut Jules Bordet, Brussels, BelgiumMassimo AgliettaMedical Oncology, Candiolo Cancer Institute and University of Torino Medical School, Candiolo, ItalyPilar García‐AlfonsoMedical Oncology, Hospital Gral Universitario Gregorio Marañon, Madrid, SpainBart NeynsGabriele LuppiOncology and Hematology, University Hospital of Modena, Modena, ItalyDana B. CardinDepartment of Medicine, Vanderbilt – Ingram Cancer Center, Nashville, TN, USATomislav DragovichMedical Oncology and Hematology, Banner MD Anderson, Gilbert, AZ, USAUsman ShahHematology-Medical Oncology, Lehigh Valley Hospital, Allentown, PA, USAA. AtasoyR&D Oncology Clinical Development, Bristol-Myers Squibb Company, Princeton, NJ, USARoelien PostemaHEOR, Bristol-Myers Squibb Company, London, UKZachary BoydOncology Translational Medicine, Bristol-Myers Squibb Company, Princeton, NJ, USAJean-Marie LedeineBiostatistics, Bristol-Myers Squibb Company, Princeton, NJ, USAMichael J. OvermanGastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USASara LonardiMedical Oncology, Istituto Oncologico Vento IOV-IRCSS, Padua, Italy
2018en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0